Liraglutide Injection
Product Images NDC 0143-9144

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 0143-9144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Structural Formula Of Liraglutide (Liraglutide Injection 1)

Diagram illustrating the molecular structure of liraglutide, highlighting its amino acid sequence and a attached C-16 fatty acid (palmitoyl) group. Certain amino acids (Glu and Arg) are emphasized in blue, with an arrow indicating a structural relationship between Arg and Lys residues.*

FDA Label Image

Flow Check Symbol (Liraglutide Injection 10)

Liraglutide 6 mg/mL injection label from Hikma Pharmaceuticals USA Inc. The label displays the product name Liraglutide, strength 6 mg/mL, dosage form as injection for subcutaneous use, and the NDC 0143-9144. The label includes storage and handling instructions, barcodes, and regulatory details.*

FDA Label Image

Fig. E (Liraglutide Injection 11)

An instructional illustration showing a user's hands performing a flow check on a subcutaneous injection pen. The image highlights the flow check symbol selection on the pen with an arrow indicating a twist or removal action. A close-up inset shows the flow check symbol on the device.*

FDA Label Image

Figure F (Liraglutide Injection 12)

An instructional illustration showing a hand holding a syringe with the needle tip surrounded by curved lines, indicating movement or vibration. This likely demonstrates a technique related to preparing or administering an injection.*

FDA Label Image

Figure G (Liraglutide Injection 13)

An instructional illustration depicting a hand holding a liraglutide injection pen, showing the removal of a cap or cover from the pen tip by pulling it upwards. A close-up inset highlights the pen tip with an air bubble, and a display on the pen shows a dose set to zero mg, indicating preparation steps before injection.*

FDA Label Image

Figure H (Liraglutide Injection 14)

An instructional illustration showing a person using their thumb to pull back a blue protective cap from a pen-style injection device. The image focuses on the hands and the upper portion of the injector, demonstrating how to remove the cap before use.*

FDA Label Image

Figure I (Liraglutide Injection 15)

An instructional illustration showing a hand holding a syringe injection device, demonstrating the removal of a protective cap by twisting and pulling it off before use.*

FDA Label Image

Figure J And K (Liraglutide Injection 16)

An instructional illustration showing two steps labeled J and K for preparing a syringe injection. Step J depicts grasping and pulling off a cap from the syringe needle. Step K demonstrates removing an additional protective cover, indicated by an arrow, preparing the syringe for use.*

FDA Label Image

Fig. L (Liraglutide Injection 17)

An instructional illustration showing a subcutaneous liraglutide injection pen with a dial to select doses. The image highlights dose options of 0.6 mg, 1.2 mg, and 1.8 mg, each shown with a corresponding dial setting on the pen. The illustration visually guides users on selecting the dose prior to injection.*

FDA Label Image

Fig. M (Liraglutide Injection 18)

An instructional illustration showing a hand holding a liraglutide injection pen. The thumb is pressing down on the dose button, indicated by a large downward arrow, while a dose window displays '0 mg,' depicting how to administer a subcutaneous injection using the device.*

FDA Label Image

Figure N (Liraglutide Injection 19)

An instructional illustration showing a hand pressing down on a liraglutide injection pen with a downward arrow indicating the action. Below the pen is a stopwatch displaying 6 seconds, likely indicating the recommended injection time.*

FDA Label Image

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration Following Single-dose Liraglutide Injection 7.5 Mcg/kg (~ 0.7 mg) Or Placebo In Patients With Type 2 Diabetes (n=10) During Graded Glucose Infusion (Liraglutide Injection 2)

A scatter plot comparing insulin secretion rates (ISR) in pmol/kg/min versus plasma glucose levels in mg/dL. The chart displays data for Liraglutide Injection and placebo groups, showing increasing ISR with higher plasma glucose, with Liraglutide Injection demonstrating consistently higher ISR than placebo across the glucose range.*

FDA Label Image

Figure O (Liraglutide Injection 20)

Illustration showing the initial step of administering Liraglutide injection subcutaneously. It depicts a syringe held vertically with an upward arrow indicating preparation or removal from the skin surface.*

FDA Label Image

Figure P (Liraglutide Injection 21)

An instructional diagram showing the attachment of a needle to a prefilled injection pen, indicated by an arrow pointing from the needle towards the pen's tip. This image is likely used for guidance on preparing a subcutaneous injection with the Liraglutide injection pen.*

FDA Label Image

Figure Q (Liraglutide Injection 22)

An instructional illustration showing a close-up of hands manipulating a medical injection pen. One hand holds the pen barrel, and the other hand is pulling back on a gray-colored part of the device, indicated by a blue arrow pointing away from the pen, suggesting the step to prepare the injection pen before use.*

FDA Label Image

Carton 3pk-268108-6 (Liraglutide Injection 23)

Carton packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) subcutaneous injection by Hikma Pharmaceuticals USA Inc. The label shows a blue injection pen and indicates the package contains 3 pens. Instructions note use as directed by healthcare professionals, refrigeration requirements, single patient use, and that the pen delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg. Manufactured by Hybio Pharmaceutical Co. Ltd., Shenzhen, China.*

FDA Label Image

Carton 2pk-268109-6 (Liraglutide Injection 24)

Label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) subcutaneous injection by Hikma Pharmaceuticals USA Inc. The label shows 2 pens per package with images of the blue injection pens. Key text includes dosage, usage instructions, refrigeration requirements, and manufacturer information. The label is for prescription use only and specifies single patient use.*

FDA Label Image

Figure 3 Mean Hba1c For Patients Who Completed The 52-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 52 (monotherapy) (Liraglutide Injection 3)

A line graph showing mean HbA1c (%) over 52 weeks comparing Glimepiride, Liraglutide Injection 1.2 mg, and Liraglutide Injection 1.8 mg. The y-axis ranges from 6.5 to 9.0%, and the x-axis shows time in weeks from 0 to 52. Both doses of Liraglutide show a greater reduction in HbA1c compared to Glimepiride, with significance markers noted.*

FDA Label Image

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (Liraglutide Injection 4)

A line graph comparing mean HbA1c (%) over time (weeks) among three groups: Liraglutide Injection 1.2 mg, Liraglutide Injection 1.8 mg, and Sitagliptin 100 mg. The graph shows HbA1c levels decreasing over 26 weeks for both liraglutide doses, with smaller reduction for sitagliptin. Statistical significance markers indicate liraglutide groups had significantly different results compared to sitagliptin.*

FDA Label Image

Liraglutide Injection Pen Diagram (Liraglutide Injection 5)

An instructional diagram of the Liraglutide Injection Pen showing its components labeled: pen cap, rubber stopper, cartridge, cartridge trip, cartridge scale, dose display, dose selector, pointer, dose button, and a flow check symbol indicator. Also includes labels for needle parts: outer needle cap, inner needle cap, needle, and protective tap. Contact information for Hikma Pharmaceuticals USA is provided for usage assistance.*

FDA Label Image

Figure A (Liraglutide Injection 6)

An instructional illustration showing a close-up of hands manipulating a device, likely an injection pen. The image highlights holding and pulling or removing the cap or cover from the pen, indicated by a blue arrow pointing outward. No text or additional instructions are visible.*

FDA Label Image

Figure B (Liraglutide Injection 7)

An instructional illustration showing a hand twisting the cap off a Liraglutide injection pen, highlighting the first step in preparing the subcutaneous injection for use.*

FDA Label Image

Figure C (Liraglutide Injection 8)

An instructional illustration showing a hand removing the protective cap from the needle of a subcutaneous injection pen. The image includes a blue arrow indicating the direction to pull the cap off the pen before administration.*

FDA Label Image

Figure D (Liraglutide Injection 9)

An instructional illustration showing a hand holding a syringe near the cap or seal, with an arrow indicating the direction to pull or remove the cap. The image likely demonstrates a step in preparing the liraglutide injection for use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.